Chi-Med CEO: New NSCLC Data Boosts Prospects For cMET Inhibitor Savolitinib
Executive Summary
Good additional data from trials of Chi-Med's savolitinib in non small cell lung cancer was presented at this year's AACR meeting which should help speed the cMET inhibitor's validation and eventual launch, the China-based group's CEO tells Scrip.